心肌梗死后心力衰竭

  • A+
所属分类:疗效
摘要

心脏衰竭(HF)心肌梗死(MI)是复杂常见并且可以存在在入院或住院期间发展。在巴蒂…

药道网 - 药到病除,助力生命汇聚全球药品资讯:
心肌梗死后心力衰竭

摘要

心力衰竭(HF)心肌梗死(MI)复杂化是常见的和可以存在在入院或住院期间发展。在MI患者,有心衰的程度和死亡率之间存在密切的关系。与HF复杂MI患者的最佳管理根据自梗死发病时间而变化。 MI后HF医疗疗法包括血管紧张素转化酶抑制剂的早期(24小时内)开始和早期(内7天)使用醛固酮拮抗剂的。另外,患者心肌梗死和持续的HF,早期使用(<24 h) of beta-blockers is associated with an increased risk of cardiogenic shock and death. Long-term beta-blocker use after MI is associated with a reduced risk of reinfarction and death. Thus, it is critical to frequently re-evaluate beta-blocker eligibility among patients after MI with HF. Cardiogenic shock is an extreme presentation of HF after MI and is a leading cause of death in the MI setting. The only therapy proven to reduce mortality for patients with cardiogenic shock is early revascularization. Several studies are examining new approaches to mitigate the occurrence and adverse impact of post-MI HF. These studies are testing drugs for HF and diabetes and are evaluating mechanical support devices to bridge patients to recovery or transplantation.

中央插图

心肌梗死后心力衰竭下载:下载高分辨率图片(419KB)下载:下载完整大小的图片

关键词

急性心肌infarctionheart failuretreatment

缩略语

CardiologyACEIangiotensin转化酶inhibitorAHAAmerican心AssociationAMIacute心肌infarctionBNPB型利尿钠peptideCABGcoronary搭桥graftCIconfidence intervalCVcardiovascularEFejection fractionHFheart failureIABPintra主动脉内球囊的ACCAmerican学院pumpMImyocardial infarctionMRAmineralocorticoid受体antagonistORodds ratioPCIpercutaneous冠状动脉interventionRRRrelative风险reductionSTEMIST-段心肌梗死

博士。格兰杰得到资金从艾伯维,阿斯利康,拜耳,勃林格殷格翰公司,波士顿科学公司,施贵宝,礼来,第一三共,Gilead公司,葛兰素史克,罗氏公司,杨森制药,美第奇网元公司,美敦力基金会,美敦力公司,诺华公司,Sirtex,辉瑞,Verseon和Armetheon。所有其他作者报告说,他们没有与本文相关披露内容的关系。

查看摘要

  • 微信咨询
  • 这是我的微信扫一扫
  • weinxin
  • WhatsApp 沟通
  • 手机扫一扫二维码
  • weinxin

发表评论

:?: :razz: :sad: :evil: :!: :smile: :oops: :grin: :eek: :shock: :???: :cool: :lol: :mad: :twisted: :roll: :wink: :idea: :arrow: :neutral: :cry: :mrgreen: